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Abstract 
Currently, endothelial dysfunction is considered as a predictor of a number of pathologies, including arterial hypertension, 
ischemic heart disease, chronic heart failure, and is also a pathogenetic component of organ damage in diabetes, hypo 
estrogenic and other conditions. The purpose of the study is an experimental study of the cardio and vasoprotective effects 
of etoxidol under conditions of endothelial dysfunction. 
Materials and methods: The study was performed on Wistar rats. The pharmacological properties of ethyl methyl 
hydroxyl pyridine malate (etoxidol) were studied on the model of endothelial dysfunction caused by the blockade of NO 
synthase on the background of the seven-day administration of L-NAME (25 mg / kg). To evaluate the effect of etoxidol on 
endothelial function, a calculated index of functional vascular samples — the coefficient of endothelial dysfunction — was 
used, and the morphological picture of the myocardium (determined the diameter of cardiomyocytes), carotid arteries 
(intima / media ratio) and adrenal mass was studied. 
Results: The seven-day administration of L-NAME led to the development of severe endothelial dysfunction. The use of 
etoxidol in a dose of 50 mg / kg against a background of relatively high blood pressure values reduced QED by 30%, and 
by 49% when using a dose of 90 mg / kg. With a relatively high diameter of cardiomyocytes in all studied groups receiving 
L-NAME, a significant (p≤0.05) difference with the control was obtained with a dose of 90 mg / kg. When studying the 
intima / media ratio in the carotid artery, a significant decrease in the ratio to the control was obtained in the group 
receiving etoxidol at a dose of 90 mg / kg. 
Conclusion: Etoxidol has a pronounced endothelial-, vaso- and cardio protective activity. The effectiveness of the drug is 
dose-dependent: the best endothelium and cardio protective effects are achieved with a dose of 90 mg / kg. 
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Introduction 
Despite significant advances in medical science in 
the field of cardiology, the number of patients 
suffering from cardiovascular diseases is growing 
steadily, and a universal tool for the prevention and 
treatment of this ailment has not yet been developed. 
In recent years, many experimental and clinical 
studies have been published on the role of endothelial 
dysfunction (ED) in the onset and progression of a 
number of cardiovascular diseases (atherosclerosis, 
hypertension, ischemic heart disease, myocardial 
infarction, and others) [1-3]. 
Endothelial dysfunction is understood as an 
imbalance between the formation of vasodilating, 
atrombogenic, antiproliferative factors, on the one 
hand, and vasoconstrictive, prothrombotic and 
proliferative substances that the endothelium 
synthesizes, on the other.  
Hemodynamic causes, age-related changes, free 
radicaldamage dyslipoproteinemia, hypercytokinemia, 
hyperhomocysteinemia, exogenous and endogenous 
intoxications can contribute to the formation of 
endothelial dysfunction [4,5]. Endothelial dysfunction 
can lead to structural damage in the body: acceleration 
of apoptosis, necrosis, and desquamation of 
endotheliocytes [6]. However, functional changes in 
the endothelium, as a rule, precede morphological 
changes in the vascular wall [7, 8]. 
In this regard, the search and study of compounds 
with the ability to improve endothelial function, is one 
of the main tasks of modern pharmacology. One of 
the fundamentally significant approaches to the 
correction of endothelial dysfunction is the use of 
drugs with antioxidant and cytoprotective activity [9-
13]. Experimental work on the modeling of arterial 
hypertension in animals has shown that an increase in 
reactive oxygen species leads to endothelial 
dysfunction, which is confirmed by an improvement 
in endothelium-dependent relaxation with the use of 
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antioxidants [14]. The development of endothelial 
dysfunction with excessive formation of reactive 
oxygen species has been confirmed in experimental 
models of type 2 diabetes and chronic renal failure in 
animals [15]. 
One of the drugs with an antioxidant orientation of 
pharmacological action is a derivative of 3-
hydroxypyridine – ethyl methyl hydroxyl pyridine 
malate (etoxidol), the establishment of the ability of 
which to positively influence the myocardium and 
blood vessels was the main objective of the study. 
Materials and Methods 
The study was performed on white rats, males, 
Wistar line, weighing 200-220g., Obtained from the 
nursery "Stolbovaya" (Pushchino, Moscow region) 
and passed the 14-day quarantine regime. The 
maintenance of animals complied with the rules of 
laboratory practice when conducting preclinical 
studies in the Russian Federation (GOST Z 51000.3-
96 and 51000.4-96) and the Order of the Ministry of 
Health of the Russian Federation No. 267 dated June 
19, 2003 ―On Approval of Laboratory Practice Rules‖ 
(GLP) in compliance with the International 
conventions for the protection of vertebrate animals 
used in experimental studies (1997). 
Endothelial dysfunction was modeled by daily 
administration of nitro-L-methyl ether (L-NAME) at a 
dose of 25 mg / kg 1 time per day intraperitoneally for 
7 days. 
The animals were divided into several groups (n = 
10): 1 - intact, which were injected intraperitoneally 
with saline 1 ml / kg 1 time per day for 7 days, then 
filtered intragastrically filtered water 1 ml / kg for 7 
days (n = 10 ); 2 - control, with the introduction of L-
NAME and saline intragastrically (1 ml / kg, 1 time 
per day); 3 - etoxidol 50 mg / kg 2 times a day during 
the administration of L-NAME; 4 - etoxidol 90 mg / 
kg 2 times a day on the background of the 
introduction of L-NAME. The study drug was 
administered through an intragastric probe daily for 7 
days. 
On the 8th day, experimental animals fixed on a 
heated surface under general anesthesia (chloral 
hydrate 150 mg / kg + zoletil 60 mg / kg 
intraperitoneally) were recorded using a carotid artery 
catheter connected to a TDS-144A sensor (Biopac, 
USA) cardiohemodynamic indicators - systolic blood 
pressure (SBP), diastolic blood pressure (DBP), heart 
rate (HR). Vasodilator vascular samples: 
endothelium-dependent (acetylcholine, 40 µg / kg) 
and endothelium-independent (sodium nitroprusside 
30 µg / kg) sample, was made by bolus administration 
of vasodilators into the left femoral vein. To 
objectively assess the severity of endothelial 
dysfunction development in experimental animals, as 
well as the extent of its correction by the studied 
pharmacological agent, we used the calculated 
coefficient of endothelial dysfunction (QED) 
proposed in our laboratory [16], Characterizing the 
degree of endothelial dysfunction and reflecting the 
ratio of the area above the blood pressure recovery 
reaction in response to the introduction of sodium 
nitroprusside (NP) to the area above the blood 
pressure recovery reaction in response to the 
introduction of acetylcholine (AH ) (Fig. 1, 2).  
 
Figure -1: Curves of the indices of cardiohemodynamics during the functional test for endothelium-
dependent vasodilation (intravenous administration of acetylcholine 40 µg / kg) in animals with L-NAME-
induced deficiency of nitric oxide. 
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Figure-2: Curves of the indices of cardiohemodynamics during the functional test for endothelium-
independent vasodilation (intravenous administration of nitroprusside 30 µg / kg) in animals with L-NAME-
induced nitric oxide deficiency. 
After carrying out vascular samples, animals were 
anesthetized (chloral hydrate 300 mg / kg 
intraperitoneally), for histological examination, the 
heart and carotid artery were removed, which were 
fixed in 10% neutral formalin and stained in a 
standard way using hematoxylin / eosin.  
In addition, in order to determine the mass of the 
glands, the adrenal glands were removed from the 
animals. 
The reliability of changes in the parameters 
observed during the action of the substance studied 
was determined by a differential method of 
descriptive statistics with finding the mean values of 
shifts (M), the average error of the arithmetic average 
(± m) and the probability of a possible error (p) 
calculated using T-test for groups with different 
dispersions. Differences were considered significant 
at p <0.05. Statistical calculations were performed 
using the STATISTICA 10.0 program. 
Results 
Evaluation of endothelial function. The blockade 
of NO-synthase, caused by the seven-day 
administration of L-NAME, led to a significant 
increase in SBP, DBP and QED (Table 1). 
Experimental animals treated with the studied drug 
showed a positive dynamics of indicators - a decrease 
in the values of these parameters; however, there was 
no significant decrease in blood pressure and QED to 
the level of intact animals. So, when using etoxidol at 
a dose of 50 mg / kg against a background of 
relatively high blood pressure values, QED decreased 
by 30%, and by 49% when using the drug at a dose of 
90 mg / kg. 
Table -1: Systolic (SBP), diastolic (DBP) blood 
pressure and endothelial dysfunction coefficient 
(QED) in rats after administration of etoxidol (M ± 
m; n = 10). 
experimental group SBP DBP QED 
intact 118.2±2.2 83.4±2.6 0.98±0.05 
control 179.4±1.9* 132.5±4.5* 4.65±0.48* 
L-NAME + etoxidol 
50 mg / kg 
173.8±4.7* 122.8±3.6* 3.22±0.30*# 
L-NAME + etoxidol 
90 мг/кг 
171.3±3.9* 116.0±3.7*# 2.25±0.21*# 
* - p≤0.05 confidence when compared with a 
group of intact animals; # - p≤0.05 when compared 
with the control group. 
Histological examination. The morphological 
study of the myocardium also revealed a positive 
trend in the application of the studied drug (Fig. 3, 4, 
5). 
 
Figure - 3: Histological picture of the myocardium 
(left ventricular wall) of rats treated with L-NAME 
(25 mg / kg) for 7 days. Hematoxylin and eosin. × 
400 
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Figure- 4: Histological picture of the myocardium 
(left ventricular wall) of rats treated with etoxidol 
(50 mg / kg) for 7 days on the background of the 
introduction of L-NAME (25 mg / kg). Hematoxylin 
and eosin. × 400 
 
Figure -5: Histological picture of the myocardium 
(left ventricular wall) of rats treated with etoxidol 
(90 mg / kg) for 7 days against the background of 
the introduction of L-NAME (25 mg / kg). 
Hematoxylin and eosin. × 400 
With a relatively large diameter of cardiomyocytes 
in all studied groups treated with L-NAME, a 
significant (p≤0.05) difference with the control was 
obtained with the administration of etoxidol at a dose 
of 90 mg / kg (Table 2). 
Table -2: The average diameter of 
thecardiomyocytes of the left ventricular wall in 
animals with L-NAME-induced deficiency of nitric 
oxide after administration of etoxidol (M ± m, n = 
10). 




L-NAME + etoxidol 50 
mg / kg 
14.28±0.03* 
L-NAME + etoxidol 90 
мг/кг 
13.98±0.03*# 
* - significant difference with the group of intact 
animals (p≤0.05); # - significant difference with the 
control group (p≤0.05). 
When studying the ratio of intima / media in the 
carotid artery, a significant decrease in the ratio 
relative to the control in the group receiving a large 
dose of etoxidol was established (Table 3). 
Table- 3: Effect of etoxidol on the intima / media 
ratio in animals with L-NAME-induced deficiency of 
nitric oxide (M ± m, n = 10). 
experimental group intima / media ratio 
intact 0.228±0.013 
control 0.379±0.028* 
L-NAME + etoxidol 50 mg / kg 0.320±0.021* 
L-NAME + etoxidol 90 мг/кг 0.290±0.034# 
Note: * - significant difference with the group of 
intact animals (p≤0.05); # - significant difference with 
the group L-NAME (p≤0.05).  
The mass of the adrenal glands. When studying the 
mass of the adrenal glands, no data were obtained 
indicating a significant change in their mass upon 
administration of etoxidol (Table 4).  
This indicates the absence of a pronounced effect 
of etoxidol on the L-NAME-dependent adaptive 
response of the adrenal glands.  
Table- 4: Effect of etoxidol on adrenal mass in 
animals with L-NAME-induced deficiency of nitric 
oxide (M ± m, n = 10). 
experimental group adrenal mass (g) 
intact 0.019±0.004 
control 0.021±0.004 
L-NAME + etoxidol 50 mg / kg 0.021±0.002 
L-NAME + etoxidol 90 мг/кг 0.022±0.004 
Conclusion 
A study of the activity of etoxidol in modeling L-
NAME induced nitric oxide deficiency demonstrated 
its pronounced endothelium protective effect, which 
was reflected in the prevalence of endothelium-
dependent vascular relaxation and a decrease in the 
rate of endothelial dysfunction (QED).  
At the same time, the cardio protective effect of 
the drug was revealed, which is expressed in the 
ability to reduce the diameter of the cardiomyocytes 
with L-NAME-induced deficiency of nitric oxide.  
Thus, the obtained results allow us to state that the 
study drug ―Etoxidol‖ is a promising endothelium and 
cardio protective agent, which is consistent with the 
data of numerous studies [17-19]. 
The study of the histological picture of the 
vascular wall showed a decrease in the intima / media 
ratio under the influence of etoxidol, which indicates a 
decrease in the proliferative processes (remodeling) of 
blood vessels, which was not previously described in 
the scientific literature. 
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